In December 28, 1875, Biirstenmacher LUDWIG FRECKMANN, who was 58 years old, was brought into the GSttingen hospital. He was suffering from diabetes mellitus. In spite of various kinds of treatment, his urinary sugar varied between 50 and 200 g and the urine volume between 2 and 41 per day until February 1876. Then WILH]~LM EBSTEI~, at that time professor of medicine at G5ttingen, started to treat ]~iirstenma-cher F~CKMAN~ with 5 g of sodium sa]icylate per day. Within a few days the urine was sugar-free. The patient continued to take 5 g a day, and at follow up in May 1876 there was no sugar demonstrable by Fehling's L6sung in the urine and he had increased in weight from 151 to 169 Pf [12] .
I wanted to begin this lecture with a summary of this interesting case because Biirstenmacher FRECK-MA~ is probably the first reported case treated with an antilipoIytic agent. I shall later come back and demonstrate that salicylates are antilipolytic compounds.
What is lipolysis in adipose tissue ?
Lipolysis in adipose tissue is the process by which the stored triglycerides (TG) are hydrolyzed to yield fatty acids and glycerol. The ]ipolytic process is schematically depicted in Fig. 1 . The result of lipolysis is mobilization of the fatty acids and the glycerol liberated by the hydrolysis. The fatty acids enter the blood and are immediately bound to albumin. They are then known as free fatty acids (FFA). Lipolysis is thus one fundamentM process controlling mobilization of FFA. Another important process in this regard is the reesterification process (Fig. 1 ). This is, however, beyond the scope of this lecture. 
l~egulation of lipolysis in adipose tissue
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Physiologic role of FFA mobilization
The physiologic role of FFA mobilization is to supply the various tissues of the body, except the central nervous system, with energy substrate as shown in Table 2 .
Metabolism of FFA
The Mbumin-bound FFA are utilized by most tissues, except the nervous tissues, to yield energy and carbon dioxide as shown in Fig A great part of the caloric intake --fat as well as carbohydrate --is stored for some time in adipose tissue as TG until needed. They are then mobilized as FFA by means of lipolysis. fled, and stored as TG until the fatty acids are split off and oxidized to yield energy. In the liver there are two additional pathways for FFA. They may be incorporated into the TG-fraction that is incorporated into the triglycerides of plasma ]ipoproteins (very low density lipoproteins). In this way the fatty acids are re-circulated into plasma and may be transported to adipose tissue and other tissues. Furthermore, the fatty acids may be oxidized in the liver to yield ketone bodies (Fig. 2) .
There is one feature of the metabolism of FFA that is of special importance for the development of various pathologic conditions. Animal studies have indicated that the uptake of FFA in various tissue is proportional to the amount of FFA perfusing the tissue [22, 13] . We have demonstrated that the same is true in man for the splanchnic region [11] . This means that it is not a tissue in itself that regulates the uptake of FFA, but rather the rate of mobilization of FFA. Thus antilipolytic agents might be assumed to reduce tissue uptake of FFA.
Excessive mobilization of 2~FA
When the mobilization of FFA is excessive in relation to the demands of the energy metabolism, the events depicted in Fig. 3 may occur. Increased tissue levels of TG, hypertriglyceridaemia and ketonaemia are all sequences of excessive FFA metabolism, and these symptoms are all well known to occur also in diabetes mellitus. In addition to these effects, high plasma levels of FFA have also been suggested to cause insuhn insensitivity and hyperglycaemia, the so-called RA~DL~ effect [15, 21] .
Mobilization of F.FA in diabetes mellitus
It has been known for several years that plasma FFA levels are elevated in diabetes mellitus [16, 1] . We could demonstrate that the mobilization of FFA from adipose tissue was enhanced in diabetes mellitus and will only be briefly summarized here. Nicotinic acid lowers fasting levels of FFA in plasma, as well as levels raised by cateeholamines in man and in several other species. Nicotinic acid inhibits lipolysis in isolated adipose tissue in vitro, and prevents the usual rise of cyclic-AMP (see Fig. 1 ) induced by eatecholamines in this tissue (2) . After intravenous administration, nicotinic acid is rapidly taken up by adipose tissue. It appears from these observations that nicotinic acid should be
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Ketones, H-A Fig. 3 . Excessive mobilization of FFA. This syndrome is caused by an exaggerated rate of mobilization of FFA and may induce, among other things, increased TG pools in various tissues, including blood and also ketonaemia [5] . This work was then extended in great detail, by 0STMA~r [18] confirming increased lipolysis in adipose tissue from patients with juvenile diabetes. Thus FFA mobilization is increased in diabetes mellitus and many, if not all, of the metabohc derangements of diabetes might be induced by excessive FFA mobilization.
To assess the role of excessive FFA mobilization, caused by increased lipolysis, for metabolic abnormalities in diabetes melhtus such as ketosis, hyperglycaemia, fatty liver, and hypertriglyeeridaemia we wanted to use an agent other than insulin with antilipolytic properties.
The observations mentioned in the introduction made us study acetyl-salieylate in this regard. We found that it was indeed an inhibitor of FFA mobilization and of lipolysis in adipose tissue [6] . This compound had several disadvantages, however, it had to be used in high doses and it was a rather weak inhibitor. Instead of applying salicylates in the study of diabetes, we continued to look for other antilipolytic agents. A potent antilipolytie compound was then found in nicotinic acid [10] .
Nicotinic acid as antilipolytie agent
The actions of nicotinic acid on FFA mobilization and on lipolysis have been reviewed elsewhere [10, 3, 4] , an ideal antilipolytic agent. Unfortunately it has, apart from clinical side effects such as flush, some disadvan. rages. One of these is the rebound phenomenon [10, 19] , which has to be carefully considered during prolonged treatment with nicotinic acid.
Effect of nicotinic acid on FFA and lipolysis in eli. nical and experimental diabetes
Nicotinic acid was found to lower plasma FFA levels in diabetic patients [7] . The increased FFA levels [8] and the increased lipolytie rate in adipose tissue [17] seen in alloxan-diabetie rats are also depressed by nicotinic acid. Nicotinic acid completely prevents the increase in plasma FFA levels seen in the acute insulin. deficiency syndrome produced by administration of anti-insuliu serum, as shown in Fig. 4 [14] .
Effect of nicotinic acid on various metabolic derange. ments of the acute insulin-deficiency syndrome in rats
Administration of anti-insulin serum to rats rapidly induces a diabetic syndrome with hyperglycaemia [23] . Fig. 4 shows that 6 h after administration to rats of anti-insulin serum, the concentration of plasma FFA, plasma fl-hydroxybutyrate, plasma TG and liver TG have all increased. Nicotinic acid prevents all these increases (Fig. 4) . 
Aspects of antilipolytic agents in the future
Up to the present time, antilipolytie agents such as nicotinic acid have been most useful as experimental tools in the study of various abnormalities in diabetes. 
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Effect of nicotinic acid on lcetosis in diabetes mellitus
Administration of nicotinic acid to_normal persons or to patients with diabetes mellit'us lowers the plasma levels of fl-hydroxybutyric ~acid [9] . In Fig. 5 a typical study in a diabetic patient is shown. The temporal relationship between the changes in blood levels of FFA and fl-hydroxybutyrate --first a fall of FFA followed by a decrease in ketones --also strongly suggests that nicotinic acid lowers ketones by reducing FFA mobilization.
o--oPLasmaFFA 2 I 9 ./umole/mL It is conceivable that the reduction of the concentration of fi-hydroxybutyrate in plasma may be caused by an increased peripheral utilization of this substrate, due to the reduced availability of the usual substrate, FFA. To study the cause of the reduced ketone levels after administration of nicotinic acid, we measured the splanchnic ketone body production in man [11] . Table 3 summarizes the results. It can be seen that the production of fl-hydroxybutyrate was reduced by 95 per cent by nicotinic acid. This fits well with the hypothesis put forward in Fig. 2 and 3 , implying an essential role of FFA mobilization, and thus lipolysis, in controlling ketone body formation.
Good clinical results have, however, been seen in diabetic ketoacidosis [20] , but an almost continuous administration is required. This is due to the hyperactive lipolysis occurring when the antilipolytic effect has vanished. This results in overshoot in FFA levels (Fig.  6 ). This may of course induce all the events occurring in the syndrome of excessive mobilization. Paradoxically, we may thus induce excessive mobilization of FFA with an antilipolytie agent. An example of that is seen in Fig. 6 , where the ketone level was increased threefold 6 h after giving 1 g of nicotinic acid by mouth. Ideally future anti]ipolytic agents should not give rise to overshoot. For longterm clinical use it would also be desirable if such agents only brought the excessive FFA mobilization back to normal, and did nob reduce the FFA mobilization into the subnormal range. Further studies on physiologically occurring, strong antilipolytic agents such as insulin and prostaglandins may be of great value for developing antilipoIytic treatment. 
